Last updated: March 3, 2026
What is the current status of regulatory approval for mixed salts of a single entity amphetamine?
Mixed salts of a single entity amphetamine, such as mixed amphetamine salts (MAS), have FDA approval for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy. Vyvanse (lisdexamfetamine) is an example of an approved product. The formulation involves different salt combinations—amphetamine sulfate, sulfate, and dextroamphetamine sulfate in fixed ratios.
What excipient strategies are suited for amphetamine-based products?
Key excipients include:
- Fillers/diluents: Lactose, microcrystalline cellulose, hydroxypropyl methylcellulose. These provide bulk and aid in tablet stability.
- Binders: Polyvinylpyrrolidone (PVP), hydroxypropyl cellulose, used to ensure tablet integrity.
- Disintegrants: Cross-linked sodium carboxymethyl cellulose, croscarmellose sodium, facilitate rapid tablet breakup.
- Lubricants: Magnesium stearate, stearic acid, prevent adhesion during manufacturing.
- Coatings: Film coatings like hydroxypropyl methylcellulose or ethylcellulose can modify drug release.
Specialized excipients include:
- Controlled-release polymers: Ethylcellulose, methacrylate-based copolymers for extended-release formulations.
- pH modifiers: To optimize solubility and absorption, such as sodium bicarbonate or citric acid.
How do excipient choices influence product stability, bioavailability, and abuse deterrence?
Stability: Excipients like antioxidants (e.g., ascorbic acid) slow oxidation of amphetamine salts. Humectants reduce moisture ingress, preventing degradation.
Bioavailability: Disintegrants and solubilizers ensure rapid release and absorption, especially in formulations requiring immediate or modified release.
Abuse deterrence: Use of tamper-resistant excipients, such as polymers that inhibit crushing or dissolution (e.g., crush-resistant coatings), reduces abuse potential.
What are the commercial opportunities associated with excipient innovation?
Market size: The global ADHD therapeutics market was valued at USD 16.55 billion in 2021, projected to grow at 8.1% CAGR (Grandview Research). Amphetamine products account for a considerable share, with new formulations offering competitive advantages.
Opportunities include:
- Extended-release formulations: Differentiated by innovative excipient systems improving pharmacokinetics, providing long-acting benefits and improved adherence.
- Abuse-deterrent formulations: Incorporating excipients that resist crushing or dissolution could meet regulatory demands and reduce diversion.
- Combination products: Co-formulation with other CNS active drugs using compatible excipients broadens therapeutic options.
Intellectual property landscape: Patents for specific excipient systems or formulations control market exclusivity. Companies with proprietary excipient compositions can achieve significant market advantages.
What are regulatory considerations for excipient selection?
- GRAS status: Excipients must have Generally Recognized As Safe (GRAS) status or equivalent.
- Compatibility: Compatibility with amphetamine salts and stability under storage conditions.
- Labeling and documentation: Regulatory submissions must include detailed excipient profiles and stability data.
- Abuse-deterrent labeling: Regulatory pathways for abuse-deterrent formulations require validation studies.
How do manufacturing processes influence excipient choices?
- Process compatibility: Excipients must withstand high-shear blending, compression, or coating processes.
- Scalability: Materials that support scale-up are prioritized.
- Cost efficiency: Selection balances performance with manufacturing costs.
Who are key players in the excipient market for amphetamine formulations?
- Dow Chemical: Supplies pharmaceutical-grade polymers.
- Ashland: Provides binders, disintegrants, and excipients.
- Colorcon: Offers film coating systems.
- Croda: Specializes in functional excipients and release modifiers.
Summary table: Excipient functions and examples
| Function |
Examples |
Purpose |
| Fillers |
Lactose, microcrystalline cellulose |
Add bulk and mechanical strength |
| Binders |
PVP, hydroxypropyl cellulose |
Hold particles together in tablets |
| Disintegrants |
Croscarmellose sodium, sodium starch glycolate |
Facilitate tablet breakup for rapid release |
| Lubricants |
Magnesium stearate |
Reduce friction during manufacturing |
| Controlled-release polymers |
Ethylcellulose, methacrylate copolymers |
Modulate drug release profile |
| pH modifiers |
Sodium bicarbonate, citric acid |
Adjust local pH for optimal drug dissolution |
Key Takeaways
- Excipient selection impacts stability, bioavailability, and abuse deterrence.
- Innovation in excipient systems supports extended-release and abuse-deterrent formulations.
- Regulatory approval hinges on excipient safety, compatibility, and stability data.
- Market growth is driven by expanding demand for ADHD therapeutics, with opportunities for differentiated, patent-protected formulations.
- Collaboration with excipient suppliers can accelerate product development and commercialization.
FAQs
-
What excipients are most effective for abuse-deterrent amphetamine formulations?
Polymers that resist crushing and tampering, such as crush-resistant coatings or thermally resistant matrices, are key. Specific examples include ethylcellulose and methacrylate-based polymers.
-
Can excipient modifications improve the bioavailability of mixed salts of amphetamine?
Yes. Solubilizers or disintegrants can enhance dissolution rates, improving absorption, especially in immediate-release formulations.
-
What are the regulatory challenges in incorporating novel excipients?
Novel excipients require comprehensive safety and stability testing and may extend approval timelines. Regulatory agencies demand detailed documentation and compatibility data.
-
How does excipient choice affect manufacturing costs?
Cost influences selection; high-performance excipients may increase costs but can produce differentiated products that justify premium pricing.
-
Are there opportunities for patent protection related to excipient systems?
Yes. Patents covering specific excipient compositions, drug release profiles, or abuse-deterrent features provide commercial exclusivity.
References
[1] Grandview Research. (2022). ADHD therapeutics market size, share & trends analysis report.
[2] U.S. Food and Drug Administration (FDA). (2021). Guidance for Industry: Abuse Deterrent Opioids—Creating a Regulatory Pathway.
[3] European Medicines Agency (EMA). (2020). Guideline on excipients in the labelling and package leaflet of medicinal products.
